Adaptive population enrichment trials can allow for a more efficient, targeted approach to drug development in precision medicine by dynamically focusing on the most promising patient subgroups as the trial progresses. This can lead to faster development of effective targeted therapies for specific patient populations. However, careful consideration of design strategies and tradeoffs are required in the planning stage.

Key topics

In this webinar we will cover:

• Statistical aspects of adaptive enrichment trials
• Regulatory requirements for pre-specification of design elements
• Benefits and Tradeoffs

Speakers

• Krishna Padmanabhan, VP Strategic Consulting